Search
5 studies match these filters. Showing 1–5 of 5 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT01574053 | Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 183 sites in total · contact listed | RecruitingNot verified since Feb 1, 2024 | 35,000target | 183 / 20 | 2012 | Feb 28, 2024 | ||
| NCT07609108 | Pridopidine Phase 3 Study in Huntington's Disease The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall worsening of HD over… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 66 sites in total · contact listed | Recruiting | Phase 3 | 400target | 66 / 12 | 2026 | Sep 17, 2026 | |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 38 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 71target | 38 / 16 | 2022 | Jun 15, 2026 | |
| NCT07190300 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 31 sites in total · contact listed | Recruiting | Phase 1 / Phase 2 | 181target | 31 / 14 | 2026 | Jun 23, 2026 | |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 279 sites in total · contact listed | Recruiting | 75,000target | 279 / 6 | 2015 | Aug 25, 2026 |